CP
DGX icon

Coho Partners’s Quest Diagnostics DGX Stock Holding History

Coho Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$17M Sell
89,103
-65,380
-42% -$11.6M 2.18% 26
2025
Q2 		$27.7M Sell
154,483
-27,780
-15% -$4.83M 2.07% 27
2025
Q1 		$30.8M Buy
+182,263
New +$29.9M 1.86% 30
2024
Q3 		– Sell
-9,678
Closed -$1.32M – 38
2024
Q2 		$1.32M Sell
9,678
-559
-5% -$76.6K 0.05% 36
2024
Q1 		$1.36M Sell
10,237
-1,596
-13% -$207K 0.03% 36
2023
Q4 		$1.63M Sell
11,833
-3,356
-22% -$441K 0.04% 41
2023
Q3 		$1.85M Sell
15,189
-2,898
-16% -$386K 0.04% 37
2023
Q2 		$2.54M Sell
18,087
-142,592
-89% -$19.7M 0.05% 36
2023
Q1 		$22.7M Buy
160,679
+2,536
+2% +$363K 0.39% 31
2022
Q4 		$24.7M Sell
158,143
-11,138
-7% -$1.6M 0.42% 30
2022
Q3 		$20.8M Buy
169,281
+37,748
+29% +$4.97M 0.39% 30
2022
Q2 		$17.5M Sell
131,533
-6,255
-5% -$852K 0.33% 31
2022
Q1 		$18.9M Buy
137,788
+10,429
+8% +$1.45M 0.31% 30
2021
Q4 		$22M Sell
127,359
-10,830
-8% -$1.65M 0.35% 33
2021
Q3 		$20.1M Sell
138,189
-24,214
-15% -$3.54M 0.33% 33
2021
Q2 		$21.4M Buy
162,403
+15,771
+11% +$2.06M 0.34% 33
2021
Q1 		$18.8M Sell
146,632
-46,582
-24% -$5.74M 0.31% 32
2020
Q4 		$23M Buy
193,214
+15,941
+9% +$1.94M 0.4% 31
2020
Q3 		$20.3M Sell
177,273
-26,808
-13% -$3.17M 0.41% 31
2020
Q2 		$23.3M Sell
204,081
-6,151
-3% -$652K 0.51% 31
2020
Q1 		$16.9M Sell
210,232
-12,086
-5% -$1.25M 0.43% 31
2019
Q4 		$23.7M Sell
222,318
-3,262
-1% -$340K 0.49% 31
2019
Q3 		$24.1M Buy
225,580
+79,669
+55% +$8.18M 0.57% 31
2019
Q2 		$14.9M Buy
145,911
+68,497
+88% +$6.58M 0.35% 30
2019
Q1 		$6.96M Buy
77,414
+8,266
+12% +$716K 0.16% 30
2018
Q4 		$5.76M Buy
69,148
+28,650
+71% +$2.69M 0.15% 32
2018
Q3 		$4.37M Sell
40,498
-442
-1% -$48.5K 0.1% 31
2018
Q2 		$4.5M Buy
40,940
+6,160
+18% +$642K 0.11% 31
2018
Q1 		$3.49M Buy
+34,780
New +$3.56M 0.09% 31

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Coho Partners's DGX Position: Q3 2025 in Review

Coho Partners reduced its Quest Diagnostics (DGX) stake by 42% in Q3 2025, selling an estimated $11.6M and leaving 89,103 shares worth $17M. The position accounts for 2.18% of the portfolio, ranked #26.

Coho Partners first reported a position in DGX in Q1 2018 and has held it in 29 quarters since. The position peaked at $30.8M in Q1 2025. 1,005 funds tracked by Wall St. Rank hold DGX as of Q3 2025.

  • Coho Partners held 89,103 shares of Quest Diagnostics worth $17M as of Q3 2025.
  • Coho Partners sold 65,380 Quest Diagnostics shares in Q3 2025, an estimated $11.6M.
  • Quest Diagnostics made up 2.18% of Coho Partners's portfolio in Q3 2025, its #26 holding.
  • Coho Partners first reported a position in Quest Diagnostics in Q1 2018 and has held it in 29 quarters since.
  • Coho Partners's Quest Diagnostics position peaked at $30.8M in Q1 2025.
  • 1,005 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2025.

Based on Coho Partners's 13F filing for Q3 2025, filed 14 Oct 2025.